|Videos|July 7, 2020

Glaucoma 360: Risk factors for glaucoma progression

Dale Heuer, MD discusses the importance of ophthalmologists identifying and providing more aggressive treatment care for patients with low/high risks of developing glaucoma.

ICYMI: Dale Heuer, MD, (retired) professor, chair of Ophthalmology and Visual Sciences at the Medical College of Wisconsin, discusses the importance of ophthalmologists identifying and providing more aggressive treatment care for patients with low/high risks of developing glaucoma, during the 2020 Glaucoma 360 conference in San Francisco, California.

See more Glaucoma 360 coverage here

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Glaucoma 360: Risk factors for glaucoma progression

Related Content

DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes

Balance Ophthalmics receives FDA 510(k) clearance for wireless-enabled nocturnal IOP device

Rising Star: Introducing Adam Jacobson, MD

When to escalate glaucoma treatment: Key lessons from three complex cases

Effects of short-term topical or systemic corticosteroids on IOP

Latest CME

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Retina Updates in Montréal

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes

First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis

NCX 470 gains positive regulatory feedback in China ahead of US NDA submission

Label Updates and Dosing Flexibility in Retinal Vascular Diseases

Real-World Experience With Aflibercept 8 mg in Retinal Vascular Diseases